Daiichi Sankyo (TYO: 4568) yesterday announced its decision to close its research subsidiary, Daiichi Sankyo India Pharma (DSIN), located in Gurgaon, India, to increase R&D productivity.
The Japanese pharma major says it is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline.
DSIN presently employs about 170 people, mainly engaged in conducting drug discovery research targeting infectious diseases and inflammation. Following its closure, the DSIN R&D pipeline (including research themes selected by the Global Health Innovative Technology Fund [GHIT Fund]) will be transferred to Daiichi Sankyo’s R&D Division.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze